Since 2011, Jim Tananbaum has been the CEO and founder of Foresite Capital. Jim has close to 25 years experience in the healthcare investment and entrepreneurial sector. Jim mainly focuses on financial, strategic, and operational opportunities to assist him in the construction of franchise healthcare companies. As a result, Jim has been the chief architect of the company’s investment strategy and organization structure as well as numerous portfolio companies. According to Jim, it is important to note that the healthcare is ever changing; therefore, there is a need to invest in that sector consistently.
Background Information on Foresite Capital
Foresite Capital is a privately held healthcare and equity company that mainly specializes in the identification of top emerging leaders in the health care industry. According to pelotontherapeutics.com, the company primarily invests in the most innovative and leading health care industries and offers growth capital to health care providers that are emerging in both the public and private sectors. With an asset value of 1.1 billion dollars, Foresite Capital has sponsored various latest investments such as Juno Therapeutics and Intarcia, a type II diabetes implant designed to help patients control their diabetes levels and weight.
About Jim Tananbaum
Jim is the man behind the success story of various healthcare investments such as Amira and Jazz Pharmaceuticals. These health care investments have paved the way for him to be named by Forbes on the Midas List of Top Tech Investors for three years consecutively, reports INC42. Jim has also served as the founding partner at two health care firms known as Prospect Venture Partners II and III Sierra Ventures.
Jim obtained an M.B.A and M.D from Harvard Business and Medical Schools respectively. In addition, he graduated from Yale University with a B.S. and B.S.E.E. and B.S major in electrical and science engineering. Jim also holds an M.S. from the Massachusetts Institute of Technology (MIT). Over the years, Tananbaum has served on advisory boards for the MIT HST program at Harvard. He has also had the opportunity of being mentored by some academicians such as George Whitesides from Harvard University, Rick Levin from Yale, and Roy Vagelos from Theravance. His interaction with these academicians has led to the establishment of productive and long-term relationships which have given him new and better insights in the health care sector.